Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucine Vuitton

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 28, 2023
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAIDRose Al Bacha, Yoram Bouhnik, Melanie Serrero, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2022
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAIDAurelien Amiot, Philippe Seksik, Jean-Marie Reimund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2023
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAIDYoram Bouhnik, Guillaume Pineton de Chambrun, Jérôme Lambert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 6, 2021
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensusLucas Guillo, Pierre Delanaye, Martin Flamant, et al.
Gastrointestinal Endoscopy|April 14, 2023
Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study)Bertrand Napoléon, Andrea Lisotti, Fabrice Caillol, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2025
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre StudyMathilde Osty, Romain Altwegg, Mélanie Serrero, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 28, 2023
Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAIDRose Al Bacha, Yoram Bouhnik, Melanie Serrero, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 16, 2022
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAIDAurelien Amiot, Philippe Seksik, Jean-Marie Reimund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 2, 2023
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAIDYoram Bouhnik, Guillaume Pineton de Chambrun, Jérôme Lambert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 27, 2016
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseAurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 6, 2021
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensusLucas Guillo, Pierre Delanaye, Martin Flamant, et al.
Gastrointestinal Endoscopy|April 14, 2023
Risk factors for EUS-guided radiofrequency ablation adverse events in patients with pancreatic neoplasms: a large national French study (RAFPAN study)Bertrand Napoléon, Andrea Lisotti, Fabrice Caillol, et al.
Alimentary Pharmacology & Therapeutics|May 22, 2025
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre StudyMathilde Osty, Romain Altwegg, Mélanie Serrero, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID StudyMathurin Fumery, Benedicte Caron, Xavier Hébuterne, et al.
Pageof 12